StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) income statement

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.01−0.27 (-2.86%)

Close on Nov 18, 2026Market cap $579.84MP/E –Yield –

See a number that looks wrong?